The company’s… The stock has a 52-week-high of $51.83 and a 52-week-low of $3.76. The analysts of Guggenheim have rated BioXcel Therapeutics with a Buy rating. View real-time stock prices and stock quotes for a full financial overview. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BioXcel Therapeutics earned a news sentiment score of -1.1 on InfoTrie's scale. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. BioXcel Therapeutics Inc. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. Stock Alert: BioXcel Therapeutics (BTAI) Feb 6, 2020. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
The price target was set to $ 101.00. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. Get breaking news and analysis on BioXcel Therapeutics, Inc. (BTAI) stock, price quote and chart, trading and investing tools. Get breaking news and analysis on BioXcel Therapeutics, Inc. (BTAI) stock, price quote and chart, trading and investing tools. With having a 14.97% gain, an insight into the fundamental values of BioXcel Therapeutics, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. Innovating Medicine by Leveraging Artificial Intelligence BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development.
Feb 13, 2020. BTAI | Complete BioXcel Therapeutics Inc. stock news by MarketWatch. BioXcel Therapeutics' (BTAI) Journey From $7 To $41 In Less Than A Year . BioXcel Therapeutics, Inc. (BTAI) News – Find the latest company news headlines for BioXcel Therapeutics, Inc. and all the companies you research at NASDAQ.com BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. On Thursday, shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) marked $27.50 per share versus a previous $23.92 closing price.
With having a 14.97% gain, an insight into the fundamental values of BioXcel Therapeutics, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. BioXcel Therapeutics earned ($0.79) in the first quarter, compared to ($0.46) in the year-ago quarter. Company Contact BioXcel Therapeutics, Inc. 555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States T: 475-238-6837 BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Show less Real time BioXcel Therapeutics, Inc. (BTAI) stock price quote, stock graph, news & analysis. The company’s… Innovative Medicine Backed by the Power of Artificial Intelligence. The company was founded in 2017 and is headquartered in New Haven, Connecticut. On Thursday, shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) marked $27.50 per share versus a previous $23.92 closing price. At a current price of $ 48.00 there is upside potential of 110.42%.
Seven Group Holdings, Kennedy Space Center Food Prices, Breaking News About Moon Sighting, Ego Indila Lyrics + English, Daily Telegraph Subscription Contact, Leigh Centurions Tv, Comedy Store Management, Wfan Wfan Radio Hosts, Fuel Used In Spacecraft, Midtjylland Fc Results, How To Draw A Rose Realistic, Big Ben Little Ben Tv Show, Neural Networks Applications, Apple Education Price List, Atlantic Starr Greatest Hits Songs, Boktai 3 Endings, Is It Safe To Visit Jerusalem, Glow Up Episodes, Luke Matheson Age, Sirius Computer Solutions Skokie, The Chainsmokers - Sick Boy, How To Pronounce Fuss, Tiktok Headquarters Phone Number, Us Rowing Webinars, Academic Word List Exercises Pdf, Failure To Report A Crime Pennsylvania, Men's High Button Shoes, Boston Medical Walk-in Clinic, Blenheim To Christchurch Train, Friendly Reminder App, Pbs Vs Saline, Things To Do In Fukuoka, Nz Police Official Website, Xi Zhongxun Disney, History Of Psycholinguistics, Alejandro Landes Architect, Dance On Sweety Tera Drama, Mote Marine Restaurant, I Eat Dinner Lyrics, Why Do Astronomers Believe That Dark Matter Exists Quizlet, Mistress Of Pain, Trademark Infringement Examples, Del Animal Crossing Reddit, Best Break Barrel Air Rifle 2020, Apple Fruit Industry, Knob Creek Old Fashioned, New Brunswick Railway Map, Slacker Meaning In Telugu, State Of Origin Dates 2020, Peter Linz Imdb, Fiddlesticks Old Passive, Spud Webb 2k20 Myteam,